Edesa Biotech, Inc. (EDSA): Price and Financial Metrics
EDSA Price/Volume Stats
| Current price | $2.19 | 52-week high | $5.59 |
| Prev. close | $2.20 | 52-week low | $1.55 |
| Day low | $2.09 | Volume | 18,783 |
| Day high | $2.20 | Avg. volume | 914,591 |
| 50-day MA | $2.04 | Dividend yield | N/A |
| 200-day MA | $2.39 | Market Cap | 15.38M |
EDSA Stock Price Chart Interactive Chart >
Edesa Biotech, Inc. (EDSA) Company Bio
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
EDSA Price Returns
| 1-mo | 14.06% |
| 3-mo | -6.41% |
| 6-mo | 29.59% |
| 1-year | -48.35% |
| 3-year | -80.92% |
| 5-year | -94.23% |
| YTD | 30.36% |
| 2024 | -63.24% |
| 2023 | -69.78% |
| 2022 | -61.63% |
| 2021 | 32.47% |
| 2020 | 3.66% |
Loading social stream, please wait...